Pazopanib and survival outcomes in soft-tissue sarcoma: a single-center experience

Authors : Mert Tohumcuoğlu, Mahmut Büyükşimşek

Pages : 1135-1144

Doi:10.17826/cumj.1803102

View : 71 | Download : 237

Publication Date : 2025-12-22

Article Type : Research Paper

Abstract :Purpose: The aim of this study was to evaluate overall and progression-free survival and explore subgroup differences in a single-center retrospective cohort of patients with advanced soft-tissue sarcoma receiving pazopanib. Materials and Methods: A single-center retrospective cohort study included 45 adults with locally advanced or metastatic non-adipocytic soft-tissue sarcoma who initiated pazopanib between March 2020 and December 2024. Data were extracted from institutional electronic records (pathology, imaging, treatment, and follow-up). Overall survival (OS; from pazopanib initiation to death) and progression-free survival (PFS; from initiation to disease progression or death) were estimated using the Kaplan–Meier method with 95% confidence intervals. Results: Forty-five patients were analyzed. Median PFS was 4.50 months (95% CI, 2.28–10.26) and median OS was 6.90 months (95% CI, 2.85–17.36); 1-year OS was 35.6%. Event rates were 82.2% for progression and 73.3% for death during follow-up. No subgroup differences reached significance for either PFS or OS; in Kaplan–Meier/log-rank comparisons, OS was numerically longer in patients with prior radiotherapy (16.53 vs 6.90 months). Conclusion: These real-world data suggest that pazopanib maintains disease control consistent with the efficacy reported in the phase III randomized trial, whereas baseline risk profile and subsequent therapies are likely to influence overall survival; these findings should be confirmed in larger prospective multicenter cohorts.
Keywords : Yumuşak Doku Sarkomu, Pazopanib, Sağkalım Sonuçları

ORIGINAL ARTICLE URL